Advertisement

Loading...

Waverunner Capital Inc.

CHM.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.05
$0.05(900.00%)
Canadian Market opens in 14h 53m

Waverunner Capital Inc. Fundamental Analysis

Waverunner Capital Inc. (CHM.CN) shows moderate financial fundamentals with a PE ratio of -0.84, profit margin of 0.00%, and ROE of 47.34%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE47.34%
Cash Position16.02%
PEG Ratio-0.24

Areas of Concern

Operating Margin0.00%
Current Ratio0.10
We analyze CHM.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 58.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
58.5/100

We analyze CHM.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CHM.CN struggles to generate sufficient returns from assets.

ROA > 10%
-93.97%

Valuation Score

Excellent

CHM.CN trades at attractive valuation levels.

PE < 25
-0.84
PEG Ratio < 2
-0.24

Growth Score

Weak

CHM.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

CHM.CN shows balanced financial health with some risks.

Debt/Equity < 1
-0.63
Current Ratio > 1
0.10

Profitability Score

Weak

CHM.CN struggles to sustain strong margins.

ROE > 15%
47.34%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is CHM.CN Expensive or Cheap?

P/E Ratio

CHM.CN trades at -0.84 times earnings. This suggests potential undervaluation.

-0.84

PEG Ratio

When adjusting for growth, CHM.CN's PEG of -0.24 indicates potential undervaluation.

-0.24

Price to Book

The market values Waverunner Capital Inc. at -0.35 times its book value. This may indicate undervaluation.

-0.35

EV/EBITDA

Enterprise value stands at -130.66 times EBITDA. This is generally considered low.

-130.66

How Well Does CHM.CN Make Money?

Net Profit Margin

For every $100 in sales, Waverunner Capital Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $47.34 in profit for every $100 of shareholder equity.

47.34%

ROA

Waverunner Capital Inc. generates $-93.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-93.97%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

CHM.CN converts -0.06% of its market value into free cash.

-0.06%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.84

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.24

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.35

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.63

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.10

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.47

vs 25 benchmark

ROA

Return on assets percentage

-0.94

vs 25 benchmark

ROCE

Return on capital employed

1.10

vs 25 benchmark

How CHM.CN Stacks Against Its Sector Peers

MetricCHM.CN ValueSector AveragePerformance
P/E Ratio-0.8428.31 Better (Cheaper)
ROE47.34%699.00% Weak
Net Margin0.00%-131318.00% (disorted) Weak
Debt/Equity-0.630.34 Strong (Low Leverage)
Current Ratio0.102775.16 Weak Liquidity
ROA-93.97%-14513.00% (disorted) Weak

CHM.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Waverunner Capital Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ